发明名称 COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
摘要 The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).;
申请公布号 US2016229865(A1) 申请公布日期 2016.08.11
申请号 US201415022248 申请日期 2014.09.18
申请人 BEIJING HANMI PHARMACEUTICAL CO., LTD. 发明人 Liu Jinming;Cha Mi Young;Li Gong;Li Zhanmei;Qiu Hongjuan;Kim Maengsup
分类号 C07D495/04;A61K31/519;A61K31/53;C07D519/00;C07D491/048;C07D487/04;A61K45/06;A61K31/5377 主分类号 C07D495/04
代理机构 代理人
主权项 1. A compound represented by formula I:wherein: R is selected from C3-8 cycloalkyl substituted by —NR2W; a 4- to 10-membered saturated N-heterocyclyl group, which contains only one nitrogen atom on its ring, and the nitrogen atom is substituted by W; or C1-4 alkyl substituted by a 4- to 10-membered saturated N-heterocyclyl group which contains only one nitrogen atoms on its ring and the nitrogen atom is substituted by W; W is selected from V is selected from C or N; X is selected from NR4, O or S; Y is selected from CH, S or O; Z is selected from CH, S, O or NR5; R1 is selected from C6-12 aryl or 5- to 12-membered heteroaryl, optionally substituted by one or more R6; R2 is selected from hydrogen or C1-8 aliphatic; R3a, R3b, and R3c are independently selected from the group consisting of hydrogen, halogen, and di(C1-8 aliphatic)aminomethyl; R4 is selected from hydrogen or C1-8 aliphatic; R5 is selected from hydrogen or C1-8 aliphatic; each R6 is independently selected from the group consisting of halogen, nitro, cyano, heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, C1-8 aliphatic, C1-8 halo aliphatic, heterocyclyl C1-8 aliphatic, hydroxy C1-8 aliphatic, C1-8 aliphaticoxy C1-8 aliphatic, C1-8 aliphaticcarbonyloxy C1-8 aliphatic, amino C1-8 aliphatic, C1-8 aliphaticamino C1-8 aliphatic, di(C1-8 aliphatic)amino C1-8 aliphatic, C1-8 aliphaticacylamino C1-8 aliphatic, C1-8 aliphaticcarbonyl C1-8 aliphatic, C1-8 aliphaticoxycarbonyl C1-8 aliphatic, aminoacyl C1-8 aliphatic, C1-8 aliphaticaminoacyl C1-8 aliphatic, di(C1-8 aliphatic)aminoacyl C1-8 aliphatic, C1-8 aliphaticsulfonyl C1-8 aliphatic, C1-8 aliphaticsulfinyl C1-8 aliphatic, C1-8 aliphaticsulfonylamino, C1-8 aliphaticsulfonylamino C1-8 aliphatic, sulfamoyl C1-8 aliphatic, C1-8 aliphaticaminosulfonyl C1-8 aliphatic, di(C1-8 aliphatic)aminosulfonyl C1-8 aliphatic, di(C1-8 aliphatic)phosphonyl C1-8 aliphatic, hydroxy, C1-8 aliphaticoxy, heterocyclyloxy, heterocyclyl C1-8 aliphaticoxy, hydroxy C1-8 aliphaticoxy, C1-8 aliphaticoxy C1-8 aliphaticoxy, amino C1-8 aliphaticoxy, C1-8 aliphaticamino C1-8 aliphaticoxy, di(C1-8 aliphatic)amino C1-8 aliphaticoxy, C1-8 aliphaticacylamino C1-8 aliphaticoxy, C1-8 aliphaticcarbonyl C1-8 aliphaticoxy, aminoacyl C1-8 aliphaticoxy, C1-8 aliphaticaminoacyl C1-8 aliphaticoxy, di(C1-8 aliphatic)aminoacyl C1-8 aliphaticoxy, amino, C1-8 aliphaticamino, di(C1-8 aliphatic)amino, heterocyclylamino, heterocyclyl C1-8 aliphaticamino, hydroxy C1-8 aliphaticamino, C1-8 aliphaticoxy C1-8 aliphaticamino, amino C1-8 aliphaticamino, C1-8 aliphaticamino C1-8 aliphaticamino, di(C1-8 aliphatic)amino C1-8 aliphaticamino, C1-8 aliphaticacylamino C1-8 aliphaticamino, C1-8 aliphaticcarbonyl C1-8 aliphaticamino, aminoacyl C1-8 aliphaticamino, C1-8 aliphaticaminoacyl C1-8 aliphaticamino, di(C1-8 aliphatic)aminoacyl C1-8 aliphaticamino, C1-8 aliphaticacylamino, heterocyclyl C1-8 aliphaticacylamino, heterocyclylacylamino, hydroxy C1-8 aliphaticacylamino, C1-8 aliphaticoxy C1-8 aliphaticacylamino, amino C1-8 aliphaticacylamino, C1-8 aliphaticamino C1-8 aliphaticacylamino, di(C1-8 aliphatic)amino C1-8 aliphaticacylamino, C1-8 aliphaticcarbonyl, heterocyclylcarbonyl, heterocyclyl C1-8 aliphaticcarbonyl, C1-8 aliphaticoxycarbonyl, heterocyclyl C1-8 aliphaticoxycarbonyl, di(C1-8 aliphatic)amino C1-8 aliphaticoxycarbonyl, aminoacyl, C1-8 aliphaticaminoacyl, di(C1-8 aliphatic)aminoacyl, heterocyclyl C1-8 aliphaticaminoacyl, heterocyclylaminoacyl, hydroxy C1-8 aliphaticaminoacyl, C1-8 aliphaticoxy C1-8 aliphaticaminoacyl, amino C1-8 aliphaticaminoacyl, C1-8 aliphaticamino C1-8 aliphaticaminoacyl, di(C1-8 aliphatic)amino C1-8 aliphaticaminoacyl, C1-8 aliphaticsulfhydryl, heterocyclylsulfhydryl, heterocyclyl C1-8 aliphaticsulfhydryl, C1-8 aliphaticsulfonyl, C1-8 aliphaticsulfinyl, heterocyclylsulfonyl, heterocyclylsulfinyl, heterocyclyl C1-8 aliphaticsulfonyl, heterocyclyl C1-8 aliphaticsulfinyl, sulfamoyl, C1-8 aliphaticaminosulfonyl, di(C1-8 aliphatic)aminosulfonyl, heterocyclyl C1-8 aliphaticaminosulfonyl, heterocyclylaminosulfonyl, di(C1-8 aliphatic)amino C1-8 aliphaticaminosulfonyl, aminosulfinyl, C1-8 aliphaticaminosulfinyl, di(C1-8 aliphatic)aminosulfinyl, heterocyclyl C1-8 aliphaticaminosulfinyl, heterocyclylaminosulfinyl, and di(C1-8 aliphatic)phosphonyl, wherein: heterocyclyl, as an independent group or a part of other group(s), represents a saturated or partially unsaturated 3- to 12-membered heterocyclyl group containing one or more heteroatoms selected from the group consisting of N, O, and S; optionally, each heterocyclyl is independently substituted by one or more substituents selected from the group consisting of halogen, C1-8 aliphatic, hydroxy C1-8 aliphatic, C1-8 aliphaticoxy C1-8 aliphatic, amino C1-8 aliphatic, C1-8 aliphaticamino C1-8 aliphatic, di(C1-8 aliphatic)amino C1-8 aliphatic, heterocyclyl C1-8 aliphatic, heterocyclyl, 5- to 12-membered heteroaryl, hydroxy, C1-8 aliphaticoxy, amino, C1-8 aliphaticamino, di(C1-8 aliphatic)amino, C1-8 aliphaticcarbonyl, heterocyclylcarbonyl, heterocyclyl C1-8 aliphaticcarbonyl, hydroxy C1-8 aliphaticcarbonyl, C1-8 aliphaticoxy C1-8 aliphaticcarbonyl, di(C1-8 aliphatic)amino C1-8 aliphaticcarbonyl, C1-8 aliphaticoxycarbonyl, aminoacyl, C1-8 aliphaticaminoacyl, di(C1-8 aliphatic)aminoacyl, C1-8 aliphaticsulfonyl, C1-8 aliphaticsulfinyl, heterocyclylsulfonyl, heterocyclylsulfinyl, heterocyclyl C1-8 aliphaticsulfonyl, heterocyclyl C1-8 aliphaticsulfinyl, sulfamoyl, C1-8 aliphaticaminosulfonyl, and di(C1-8 aliphatic)aminosulfonyl; and optionally, C6-12 aryl and 5- to 12-membered heteroaryl are independently substituted by one or more substitutents selected from the group consisting of halogen, C1-8 aliphatic, hydroxy, C1-8 aliphaticoxy, amino, C1-8 aliphaticamino and di(C1-8 aliphatic)amino, wherein C1-8 aliphatic, at each occurrence, is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl and C4-8 cycloalkenyl, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof.
地址 Beijing CN